Acceptance of tamoxifen chemoprevention by physicians and women at risk.
about
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysisAromatase expression in atypical ductal hyperplasia in women.Recruitment to a physical activity intervention study in women at increased risk of breast cancer.Willingness to use tamoxifen to prevent breast cancer among diverse women.Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug.How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.Risk-benefit profiles of women using tamoxifen for chemoprevention.Women's preferences for selective estrogen reuptake modulators: an investigation using the time trade-off technique.Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.Awareness of preventive medication among women at high risk for breast cancer and their willingness to consider transdermal or oral tamoxifen: a focus group study.Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial.A role for biomarkers in the screening and diagnosis of breast cancer in younger women.Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction.Tamoxifen vs Raloxifene vs Exemestane for ChemopreventionUsing clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive modelUptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic.Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review.Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study.
P2860
Q26773464-FFCE7DD9-426E-49CD-96EB-E040C3BB59B8Q30252881-1491B14F-F6B0-4369-B7EE-F2264CE57583Q33435670-E51D3D28-26FB-401B-AF5B-1C4B768E5996Q33688754-C9D6B5C6-CC27-4514-8DCA-05157B2D186DQ33739214-1A8B3FA8-F718-4D92-A6B8-70000296A352Q33767120-6295A76A-CD82-44D6-B51B-6B7E43CD8451Q33914381-3E05453D-4078-47D1-8494-679281566DC5Q34974865-41B3802A-2F89-40A1-A74B-E561E03B7669Q35661551-93857F79-584A-4A47-BE9C-9DFB0DA1EB4AQ35812120-CD663D15-B45F-425B-B866-83024435F417Q35836307-639A4357-EE50-41A2-9475-B8589254D12CQ35906004-0ECF298A-24A0-4AFA-9F6F-A4AD0AA4AA1CQ36950426-C838F650-E0C6-4634-818C-3B51606A18EEQ37017096-4F745E33-B86F-40A6-86C2-B5724AC7C4E3Q37097084-28FD32B0-FB8B-4B6B-8709-063A9F8D9D25Q37172219-66F78C49-C7A9-496A-9A3F-3B9E474CEE2BQ37681706-197E3C61-0A09-4E2E-8B0A-1E3FF8A594D0Q41696217-9B01AEDD-9D18-4CB9-A519-879DC0F1F3B3Q51837751-B35C558F-58CA-4F0E-8D00-E7E2DAC578D3
P2860
Acceptance of tamoxifen chemoprevention by physicians and women at risk.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Acceptance of tamoxifen chemoprevention by physicians and women at risk.
@en
type
label
Acceptance of tamoxifen chemoprevention by physicians and women at risk.
@en
prefLabel
Acceptance of tamoxifen chemoprevention by physicians and women at risk.
@en
P2093
P2860
P356
P1433
P1476
Acceptance of tamoxifen chemoprevention by physicians and women at risk.
@en
P2093
Alfred Rademaker
Julia Tchou
Nanjiang Hou
V Craig Jordan
P2860
P304
P356
10.1002/CNCR.20205
P407
P577
2004-05-01T00:00:00Z